Millipore Sigma Vibrant Logo

SCC465 BT-RMS Brain-tropic RET Melanoma-sorted Mouse Cell Line

SCC465, the BT-RMS brain-tropic RET melanoma-sorted mouse cell line, expresses mCherry and exhibits increased incidence and shortened timeline of brain metastasis post-subdermal injection.​

SCC465
Pack Size >1x10^6 viable cells/vial   
Retrieving price...
Price could not be retrieved
Minimum Quantity is a multiple of
Maximum Quantity is
Upon Order Completion More Information
You Saved ()
 
—
Request Pricing
—
Fulfillment and delivery delayed Fulfillment and delivery delayed
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

       

      Contact Customer Service

      Overview

      Replacement Information
      Description
      Catalogue NumberSCC465
      DescriptionBT-RMS Brain-tropic RET Melanoma-sorted Mouse Cell Line
      OverviewThe mouse brain-tropic RET melanoma-sorted (BT-RMS) cell line is a derivative of the Ret-melanoma sorted cell line (RMS, Cat. No. SCC462). The RMS parental cells were isolated from a spontaneously occurring skin tumor in RET transgenic mice. SCC465 cells were derived from brain tumors formed after intracardiac injection of Ret malanoma-sorted (RMS) cells.
      Alternate Names
      • BT-RMS melanoma cell line
      • brain-tropic melanoma cell line
      • RET melanoma brain cell line
      Background InformationThe RET oncogene was originally created by an accidental in-vivo recombination of two human genes, Ret and RFP (the Ret-finger protein then, known today as TRIM27), during a transformation of the NIH3T3 cells with human lymphoma DNA.1 The founder Ret transgenic mouse strains were generated by the embryonic microinjection of the RFP-Ret oncogene under the mouse metallothionein-I promoter-enhancer, and a spontaneous metastatic melanoma model line was established by repetitive rounds of back-crossing of one of such founders. The parental mouse Ret-melanoma sorted (RMS) cell line (Cat. No. SCC462), was created by engineering the isolated Ret-melanoma cells to express the fluorescent reporter gene mCherry by retroviral transduction and selecting for its high expression by FACS.

      SOURCE

      BT-RMS cells were derived from the brain tumors that formed upon the intracardiac injection of the Ret-melanoma sorted cells (RMS), which in turn were derived from the spontaneous metastatic skin tumors in Ret-transgenic mice. The founder transgenic mice were created by microinjection of the Ret transgene into the fertilized egg of (C57BL/6 x BALB/c) x BALB/c mice.2 One such founder was crossed with BCF1 (BALB/c x C57BL/6) mice to establish a transgenic line, designated “the 304 line.” When these F1 transgenic mice were subsequently crossed with C57BL/6 mice (coat color: black), BCF1 mice (agouti), and BALB/c mice (albino), benign melanocytic tumors often developed spontaneously in the pigmented F2 offspring but did not progress to metastatic tumors.2 The spontaneous metastatic melanoma model (designated the 304/B6 line), in which the parent of the SCC462 cells arose, was generated by 10 rounds of back-crossing of the 304 line with C57BL/6 mice.

      REFERENCES

      1. Takahashi M, Ritz J, Cooper GM. 1985. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 42(2): 581-588.
      2. Iwamoto T, Takahashi M, Ito M, Hamatani K, Ohbayashi M, Wajjwalku W, Isobe K, Nakashima I. 1991. Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J. 10(11): 3167-3175.
      3. Kato M, Takahashi M, Akhand AA, Liu W, Dai Y, Shimizu S, Iwamoto T, Suzuki H, Nakashima I. 1998. Transgenic mouse model for skin malignant melanoma. Oncogene. 17(14): 1885-1888.
      4. Schwartz H, Blacher E, Amer M, Livneh N, Abramovitz L, Klein A, Ben-Shushan D, Soffer S, Blazquez R, Barrantes-Freer A, et al. 2016. Incipient melanoma brain metastases instigate astrogliosis and neuroinflammation. Cancer Res. 76(15):4359-4371.
      5. Doron H, Amer M, Ershaid N, Blazquez R, Shani O, Lahav TG, Cohen N, Adler O, Hakim Z, Pozzi S, et al. 2019. Inflammatory activation of astrocytes facilitates melanoma brain tropism via the CXCL10-CXCR3 signaling axis. Cell Rep. 28(7): 1785-1798.
      References
      Product Information
      Components
      • ≥1x106 viable BT-RMS cells: (Catalog No. SCC465). Store in liquid nitrogen.
      Quality LevelMQ100
      Applications
      ApplicationSCC465, the BT-RMS brain-tropic RET melanoma-sorted mouse cell line, expresses mCherry and exhibits increased incidence and shortened timeline of brain metastasis post-subdermal injection.​
      Key Applications
      • Cell Culture
      Application NotesThis product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@milliporesigma.com.
      Biological Information
      HostMouse
      Cell Line Type
      • Cancer Cells
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Quality Assurance• Each vial contains ≥1X10⁶ viable cells.
      • BT-RMS cells are verified to be of mouse origin and negative for human, rat, Chinese hamster, Golden Syrian hamster, and non-human primate interspecies contamination, as assessed by a Contamination Clear panel by Charles River Animal Diagnostic Services
      • Cells tested negative for infectious diseases against a Mouse Essential CLEAR panel by Charles River Animal Diagnostic Services.
      • Cells tested negative for mycoplasma.
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      • This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges Merck to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.
      Storage and Shipping Information
      Storage ConditionsBT-RMS cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
      Packaging Information
      Material SizePack Size >1x10^6 viable cells/vial
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      SCC465 04065270302175